JP5649783B2 - Hcvプロドラッグ処方 - Google Patents
Hcvプロドラッグ処方 Download PDFInfo
- Publication number
- JP5649783B2 JP5649783B2 JP2008544952A JP2008544952A JP5649783B2 JP 5649783 B2 JP5649783 B2 JP 5649783B2 JP 2008544952 A JP2008544952 A JP 2008544952A JP 2008544952 A JP2008544952 A JP 2008544952A JP 5649783 B2 JP5649783 B2 JP 5649783B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solid suspension
- composition according
- poloxamer
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
Description
以下の組成物は、重量%に基づく処方を表す。
以下の組成物を調製する:
Claims (15)
- イソ酪酸(2R,3S,4R,5R)−5−(4−アミノ−2−オキソ−2H−ピリミジン−1−イル)−2−アジド−3,4−ビス−イソ−ブチリルオキシ−テトラヒドロ−フラン−2−イルメチルエステル塩酸塩(I)とポリエチレングリコール(PEG)/ポリプロピレングリコール(PPG)ブロックコポリマーとのホットメルト押出により調製される固体懸濁物を含む薬剤組成物。
- 更に、少なくとも1種の希釈剤、担体及び/又は賦形剤を含む、請求項1記載の薬剤組成物。
- 該PEG/PPGブロックコポリマーが、ポロキサマーである、請求項1記載の薬剤組成物。
- 更に、少なくとも1種の希釈剤、担体及び/又は賦形剤を含む、請求項3記載の薬剤組成物。
- 該固体懸濁物が、カプセル又は圧縮錠に含まれる、請求項3記載の薬剤組成物。
- 更に、少なくとも1種の希釈剤、担体及び/又は賦形剤を含む、請求項5記載の薬剤組成物。
- 該固体懸濁物が、(I)及びポロキサマー188を含む、請求項5又は6記載の薬剤組成物。
- 該固体懸濁物が、20〜40%(重量/重量)のポロキサマー188を含む、請求項7記載の薬剤組成物。
- 固体懸濁物が、圧縮錠に含まれ、該錠剤が、微結晶性セルロース、マンニトール、クロスポビドン、コロイド状二酸化ケイ素、トウモロコシデンプン、タルク、ステアリン酸マグネシウム、重炭酸ナトリウム、アルギニン、マルトデキストリン及びコーティング材料よりなる群から選択される、1種以上の賦形剤を含む、請求項8記載の薬剤組成物。
- イソ酪酸(2R,3S,4R,5R)−5−(4−アミノ−2−オキソ−2H−ピリミジン−1−イル)−2−アジド−3,4−ビス−イソ−ブチリルオキシ−テトラヒドロ−フラン−2−イルメチルエステル塩酸塩(I)、ポロキサマー188及び可塑剤のホットメルト押出により調製される固体懸濁物を含む薬剤組成物。
- イソ酪酸(2R,3S,4R,5R)−5−(4−アミノ−2−オキソ−2H−ピリミジン−1−イル)−2−アジド−3,4−ビス−イソ−ブチリルオキシ−テトラヒドロ−フラン−2−イルメチルエステル塩酸塩(I)とPEG/PPGブロックコポリマーとの固体懸濁物の製造方法であって、
(i) ブレンダー中で固体を混合する工程;
(ii) 生じた固体混合物をホットメルト押出機の加熱域に導入する工程であって、ここで、加熱域の温度は、該ブロックコポリマーの融点より高く(I)の融点より低い範囲にある工程;
(iii) 生じた溶融物を押し出す工程;及び
(iv) 固体懸濁物を20〜2000ミクロンの間の粒度まで粉砕する工程
を含む方法。 - 固体懸濁物が、100〜600ミクロンの間まで粉砕される、請求項14記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75014605P | 2005-12-14 | 2005-12-14 | |
US60/750,146 | 2005-12-14 | ||
US83059406P | 2006-07-12 | 2006-07-12 | |
US60/830,594 | 2006-07-12 | ||
PCT/EP2006/069262 WO2007068615A2 (en) | 2005-12-14 | 2006-12-04 | Hcv prodrug formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009519289A JP2009519289A (ja) | 2009-05-14 |
JP5649783B2 true JP5649783B2 (ja) | 2015-01-07 |
Family
ID=37806115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008544952A Expired - Fee Related JP5649783B2 (ja) | 2005-12-14 | 2006-12-04 | Hcvプロドラッグ処方 |
Country Status (21)
Country | Link |
---|---|
US (1) | US7795237B2 (ja) |
EP (1) | EP1962808B1 (ja) |
JP (1) | JP5649783B2 (ja) |
KR (1) | KR20080089344A (ja) |
AR (1) | AR058313A1 (ja) |
AT (1) | ATE482690T1 (ja) |
AU (1) | AU2006326130B2 (ja) |
BR (1) | BRPI0619890A2 (ja) |
CA (1) | CA2631498A1 (ja) |
CR (1) | CR10026A (ja) |
DE (1) | DE602006017257D1 (ja) |
DK (1) | DK1962808T3 (ja) |
EC (1) | ECSP088528A (ja) |
IL (1) | IL191791A (ja) |
MA (1) | MA30056B1 (ja) |
NO (1) | NO20082563L (ja) |
PL (1) | PL1962808T3 (ja) |
PT (1) | PT1962808E (ja) |
RU (1) | RU2435592C2 (ja) |
TW (1) | TWI382840B (ja) |
WO (1) | WO2007068615A2 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005072710A2 (en) * | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
KR101462693B1 (ko) * | 2006-08-16 | 2014-11-17 | 노파르티스 아게 | 고도 결정질 치료용 화합물의 고체 분산체 제조 방법 |
EP2061433B1 (en) * | 2006-09-08 | 2011-02-16 | Johns Hopkins University | Compositions for enhancing transport through mucus |
CA2682638C (en) * | 2007-03-29 | 2012-07-17 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising (2r, 3s, 4r, 5r)-5-(4-amino-2-oxo-2h-pyrimidin-1-yl)-2-azido-3,4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl isobutyrate |
PL2389164T3 (pl) * | 2009-01-21 | 2015-01-30 | Hoffmann La Roche | Kompozycje farmaceutyczne zawierające prolek inhibitora polimerazy HCV |
AR075180A1 (es) * | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
CN102725303B (zh) * | 2010-01-28 | 2015-05-27 | 里博科学有限责任公司 | 作为抗hcv化合物的4’-叠氮基-核苷 |
JP5671609B2 (ja) | 2010-05-10 | 2015-02-18 | ユーロ−セルティーク エス.エイ. | ヒドロモルホンおよびナロキソンを含む医薬組成物 |
BR112012028656A2 (pt) | 2010-05-10 | 2016-08-09 | Euro Celtique Sa | combinação de grânulos carregados ativos com ativos adicionais |
WO2011141489A1 (en) | 2010-05-10 | 2011-11-17 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
AU2011323250B2 (en) * | 2010-11-05 | 2015-11-19 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
EP2455068A1 (en) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmaceutical composition for treating HCV infections |
WO2012062691A1 (en) * | 2010-11-09 | 2012-05-18 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for treating hcv infections |
JP5917964B2 (ja) * | 2012-03-19 | 2016-05-18 | 富士ゼロックス株式会社 | 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP4008355A1 (en) * | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
EP3808339A1 (en) | 2012-05-03 | 2021-04-21 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
KR102194174B1 (ko) | 2013-11-13 | 2020-12-23 | 유로-셀티큐 에스.에이. | 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손 |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3381479A1 (de) * | 2017-03-29 | 2018-10-03 | ARTOSS GmbH | Trägerzusammensetzung für knochenersatzmaterialien |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2272536B1 (en) | 1996-06-26 | 2016-05-04 | Board of Regents, The University of Texas System | Hot-melt extrudable Pharmaceutical formulation |
ES2191977T3 (es) * | 1997-10-27 | 2003-09-16 | Merck Patent Gmbh | Soluciones y dispersiones en estado solido de farmacos poco solubles en agua. |
ES2231717T3 (es) * | 2001-05-03 | 2005-05-16 | F. Hoffmann-La Roche Ag | Forma de dosificacion farmaceutica del mesilato de melfinavir amorfo. |
DE10208344A1 (de) | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Schmelzextrusion von Wirkstoffsalzen |
TWI332507B (en) * | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
US20050044529A1 (en) | 2003-08-20 | 2005-02-24 | Microsoft Corporation | Task library of task data for a plurality of components on a computer system |
US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
-
2006
- 2006-12-04 DK DK06830328.8T patent/DK1962808T3/da active
- 2006-12-04 KR KR1020087014073A patent/KR20080089344A/ko not_active Application Discontinuation
- 2006-12-04 PT PT06830328T patent/PT1962808E/pt unknown
- 2006-12-04 AT AT06830328T patent/ATE482690T1/de active
- 2006-12-04 PL PL06830328T patent/PL1962808T3/pl unknown
- 2006-12-04 AU AU2006326130A patent/AU2006326130B2/en not_active Ceased
- 2006-12-04 CA CA002631498A patent/CA2631498A1/en not_active Abandoned
- 2006-12-04 EP EP06830328A patent/EP1962808B1/en active Active
- 2006-12-04 RU RU2008128361/15A patent/RU2435592C2/ru not_active IP Right Cessation
- 2006-12-04 BR BRPI0619890-2A patent/BRPI0619890A2/pt not_active IP Right Cessation
- 2006-12-04 DE DE602006017257T patent/DE602006017257D1/de active Active
- 2006-12-04 WO PCT/EP2006/069262 patent/WO2007068615A2/en active Application Filing
- 2006-12-04 JP JP2008544952A patent/JP5649783B2/ja not_active Expired - Fee Related
- 2006-12-12 AR ARP060105459A patent/AR058313A1/es not_active Application Discontinuation
- 2006-12-12 TW TW095146501A patent/TWI382840B/zh not_active IP Right Cessation
- 2006-12-13 US US11/637,999 patent/US7795237B2/en not_active Expired - Fee Related
-
2008
- 2008-05-28 CR CR10026A patent/CR10026A/es not_active Application Discontinuation
- 2008-05-28 IL IL191791A patent/IL191791A/en not_active IP Right Cessation
- 2008-06-02 NO NO20082563A patent/NO20082563L/no not_active Application Discontinuation
- 2008-06-12 EC EC2008008528A patent/ECSP088528A/es unknown
- 2008-06-16 MA MA31038A patent/MA30056B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006326130A1 (en) | 2007-06-21 |
IL191791A (en) | 2011-06-30 |
WO2007068615A2 (en) | 2007-06-21 |
CA2631498A1 (en) | 2007-06-21 |
CR10026A (es) | 2008-07-29 |
US7795237B2 (en) | 2010-09-14 |
DE602006017257D1 (de) | 2010-11-11 |
IL191791A0 (en) | 2008-12-29 |
NO20082563L (no) | 2008-07-03 |
ATE482690T1 (de) | 2010-10-15 |
PL1962808T3 (pl) | 2011-03-31 |
JP2009519289A (ja) | 2009-05-14 |
AR058313A1 (es) | 2008-01-30 |
RU2008128361A (ru) | 2010-01-20 |
TWI382840B (zh) | 2013-01-21 |
EP1962808A2 (en) | 2008-09-03 |
TW200803873A (en) | 2008-01-16 |
US20070202175A1 (en) | 2007-08-30 |
PT1962808E (pt) | 2010-10-29 |
WO2007068615A3 (en) | 2007-09-07 |
DK1962808T3 (da) | 2010-11-08 |
BRPI0619890A2 (pt) | 2011-10-25 |
KR20080089344A (ko) | 2008-10-06 |
EP1962808B1 (en) | 2010-09-29 |
ECSP088528A (es) | 2008-07-30 |
MA30056B1 (fr) | 2008-12-01 |
RU2435592C2 (ru) | 2011-12-10 |
AU2006326130B2 (en) | 2011-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5649783B2 (ja) | Hcvプロドラッグ処方 | |
JP5794650B2 (ja) | 難溶性薬物の溶解性改善製剤 | |
KR20100134557A (ko) | 고체 약제학적 투여 제형 | |
US20110034489A1 (en) | Solid dosage forms of hiv protease inhibitors | |
US7893037B2 (en) | Pharmaceutical composition and process | |
US20130267590A1 (en) | Retigabine compositions | |
TWI436765B (zh) | 用於治療hcv感染之醫藥組合物 | |
ES2350497T3 (es) | Formulación de profármacos para el vhc. | |
MX2008007428A (es) | Formulacion de profamarcos para el virus de la hepatitis c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120808 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121002 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140725 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5649783 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |